Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Maes

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 13, 2004
Combined 'en bloc' liver and pancreas transplantation in patients with liver disease and type 1 diabetes mellitusJacques Pirenne, Koen Deloose, Willy Coosemans, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 24, 2005
Beneficial effect of early initiation of lipid-lowering therapy following renal transplantationHallvard Holdaas, Bengt Fellström, Alan G Jardine, et al.
Transplantation|January 25, 2005
Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trialBengt Fellström, Hallvard Holdaas, Alan G Jardine, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 1, 2005
Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) StudyAlan G Jardine, Bengt Fellström, John O Logan, et al.
The New England Journal of Medicine|October 25, 2024
Alternative Complement Pathway Inhibition with Iptacopan in IgA NephropathyVlado Perkovic, Jonathan Barratt, Brad Rovin, et al.
Journal of the American Society of Nephrology : JASN|October 27, 2024
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA NephropathyJonathan Barratt, Sean J Barbour, Robert M Brenner, et al.
European Radiology|December 6, 2012
Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)Gilbert Deray, Olivier Rouviere, Lorenzo Bacigalupo, et al.
Kidney International|March 29, 2024
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathyRichard Lafayette, Sean Barbour, Rubeen Israni, et al.
Kidney International|November 1, 2023
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathyHong Zhang, Dana V Rizk, Vlado Perkovic, et al.
FEMS Immunology and Medical Microbiology|November 20, 2003
Performance of the VERSANT HIV-1 resistance assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypesInge Derdelinckx, Kristel Van Laethem, Bart Maes, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 13, 2004
Combined 'en bloc' liver and pancreas transplantation in patients with liver disease and type 1 diabetes mellitusJacques Pirenne, Koen Deloose, Willy Coosemans, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 24, 2005
Beneficial effect of early initiation of lipid-lowering therapy following renal transplantationHallvard Holdaas, Bengt Fellström, Alan G Jardine, et al.
Transplantation|January 25, 2005
Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trialBengt Fellström, Hallvard Holdaas, Alan G Jardine, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 1, 2005
Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) StudyAlan G Jardine, Bengt Fellström, John O Logan, et al.
The New England Journal of Medicine|October 25, 2024
Alternative Complement Pathway Inhibition with Iptacopan in IgA NephropathyVlado Perkovic, Jonathan Barratt, Brad Rovin, et al.
Journal of the American Society of Nephrology : JASN|October 27, 2024
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA NephropathyJonathan Barratt, Sean J Barbour, Robert M Brenner, et al.
European Radiology|December 6, 2012
Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)Gilbert Deray, Olivier Rouviere, Lorenzo Bacigalupo, et al.
Kidney International|March 29, 2024
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathyRichard Lafayette, Sean Barbour, Rubeen Israni, et al.
Kidney International|November 1, 2023
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathyHong Zhang, Dana V Rizk, Vlado Perkovic, et al.
FEMS Immunology and Medical Microbiology|November 20, 2003
Performance of the VERSANT HIV-1 resistance assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypesInge Derdelinckx, Kristel Van Laethem, Bart Maes, et al.
Pageof 8